A recent advance in personalized medicine happened when the U.S...Based on history, this should be a big boost for sales of Erbitux. AstraZeneca's lung cancer drug Iressa, launched in 2002, had little success because of its high failure rate. The okay for Therascreen is a milestone since the FDA...
FULL ARTICLE AT The Motley Fool